Haemonetics
HAE
294 hedge funds and large institutions have $4.3B invested in Haemonetics in 2023 Q2 according to their latest regulatory filings, with 33 funds opening new positions, 97 increasing their positions, 111 reducing their positions, and 38 closing their positions.
281% more call options, than puts
Call options by funds: $8.4M | Put options by funds: $2.21M
3% more capital invested
Capital invested by funds: $4.19B → $4.3B (+$117M)
0.71% less ownership
Funds ownership: 100.61% → 99.9% (-0.71%)
2% less funds holding
Funds holding: 300 → 294 (-6)
13% less repeat investments, than reductions
Existing positions increased: 97 | Existing positions reduced: 111
13% less first-time investments, than exits
New positions opened: 33 | Existing positions closed: 38
67% less funds holding in top 10
Funds holding in top 10: 3 → 1 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
+$34.4M |
| 2 |
Morgan Stanley
New York
|
+$22.9M |
| 3 |
Franklin Resources
San Mateo,
California
|
+$18.8M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$14.5M |
| 5 |
Boston Partners
Boston,
Massachusetts
|
+$8.11M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Envestnet Asset Management
Chicago,
Illinois
|
-$32M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$30.6M |
| 3 |
Norges Bank
Oslo,
Norway
|
-$18.8M |
| 4 |
MFS
Mirabella Financial Services
London,
United Kingdom
|
-$14M |
| 5 |
CCM
Cinctive Capital Management
New York
|
-$9.88M |
HAE Hedge Fund Activity: Q2 2023 in Review
294 of the 6,383 institutional investors tracked by Wall St. Rank reported a position in Haemonetics (HAE) for Q2 2023, worth a combined $4.3B — up 2.8% from $4.19B a quarter earlier.
Sellers outnumbered buyers: 38 funds closed out of HAE and 33 opened new positions — a net loss of 5 holders — while 111 trimmed existing stakes and 97 added.
The largest buyer was Invesco, adding an estimated $34.4M. The largest seller was Envestnet Asset Management, cutting an estimated $32M.
- 294 institutional investors held Haemonetics (HAE) as of Q2 2023, down from 300 in Q1 2023.
- Funds reported $4.3B of Haemonetics stock for Q2 2023, up 2.8% quarter-over-quarter.
- 33 funds opened new Haemonetics positions in Q2 2023 and 38 closed out, a net change of -5 holders.
- The largest Haemonetics buyer in Q2 2023 was Invesco, an estimated $34.4M added.
- The largest Haemonetics seller in Q2 2023 was Envestnet Asset Management, an estimated $32M sold.
Based on aggregated 13F filings for Q2 2023.